Inhibrx net loss widens 27.9% to $36.7 million in Q2 FY26; revenue is no revenue
INBX•Quarterly results
Inhibrx posted a GAAP net loss of $36.7 million, or $2.34 per share, in Q2 2026.
Loss widened from $28.7 million, or $1.85 per share, a year earlier.
R&D expense rose to $23.9 million; G&A expense increased to $8.3 million.
Cash and cash equivalents totaled $133.3 million at June 30, 2026; revenue was nil in Q2 2026.
Loan amendment and liquidity
Oxford amended its loan deal to add up to $325 million; $100 million was funded, lifting cash to $219.5 million at Aug. 6.
